REG - Haleon PLC - Director/PDMR Shareholding

HALEONAnnouncement

01/11/2024 10:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241101:nRSA6223Ka&default-theme=true

RNS Number : 6223K  Haleon PLC  01 November 2024

 

Haleon plc: Director/PDMR Shareholding

 

1 November 2024: Haleon plc (the "Company" or "Haleon") (LSE/NYSE:HLN) today
announces notification and public disclosure in accordance with the
requirements of The UK Market Abuse Regulation of Transactions by a Person
Discharging Managerial Responsibilities ("PDMR").

 

This notification sets out the details of the grants of Haleon share awards
over ordinary shares (grant date - 31 October 2024) made to Dawn Allen as CFO
(incoming), under the Haleon Performance Share Plan 2023 and Share Value Plan
2023.

 

Further to the announcement on 24 April 2024, relating to Dawn's appointment
as CFO with effect from 1 November 2024, Dawn has received awards to
compensate the loss of incentive payments from her previous employment. These
awards will vest subject to continued employment and performance conditions
where appropriate, and will mirror as closely as possible the value, terms and
release timeline of the forfeited awards.

 

In addition, a Performance Share Plan (Interim) award has been granted on a
pro-rated basis to reflect Dawn's start date of 28 October 2024. This award is
subject to continued employment and performance conditions over the
performance period ending 31 December 2026 (vesting in March 2027).
Performance targets were disclosed in the 2023 Annual Report and Form 20-F.

 

All awards are subject to malus and clawback provisions.

 

 1       Details of the person discharging managerial responsibilities / person closely

       associated

 a)      Name                                                             Dawn Allen

 2       Reason for the notification

 a)      Position/status                                                  Chief Financial Officer (incoming)

 b)      Initial notification /Amendment                                  Initial Notification

 3       Details of the issuer, emission allowance market participant, auction

       platform, auctioneer or auction monitor

 a)      Name                                                             Haleon plc

 b)      LEI                                                              549300PSB3WWEODCUP19

 4       Details of the transaction(s): section to be repeated for (i) each type of

       instrument; (ii) each type of transaction; (iii) each date; and (iv) each
         place where transactions have been conducted
 a)      Description of the financial instrument, type of instrument      Ordinary Shares of £0.01 each

         Identification code                                              GB00BMX86B70

 b)      Nature of the transaction                                        (i)           Grant of a conditional award under the Haleon plc

                                                                Performance Share Plan (Buyout) subject to performance conditions over a
                                                                          performance period ending 31 March 2025 (vesting in June 2025, with an
                                                                          additional post vest 2 year holding period).

                                                                          (ii)          Grant of a conditional award under the Haleon plc
                                                                          Performance Share Plan (Buyout) subject to performance conditions over the
                                                                          performance period ending on 31 December 2025 (vesting in June 2026 with an
                                                                          additional post vest 2 year holding period).

                                                                          (iii)         Grant of a conditional award under the Haleon plc
                                                                          Performance Share Plan (Buyout) subject to performance conditions over the
                                                                          performance period ending on 31 December 2026 (vesting in June 2027 with an
                                                                          additional post vest 2 year holding period).

                                                                          (iv)         Grant of a conditional award under the Haleon plc Share
                                                                          Value Plan (Buyout) vesting in November 2024 (with an additional post vest 2
                                                                          year holding period).

                                                                          (v)          Grant of a conditional award under the Haleon plc Share
                                                                          Value Plan (Buyout) vesting in June 2025.

                                                                          (vi)         Grant of a conditional award under the Haleon plc
                                                                          Performance Share Plan (Interim) subject to performance conditions over the
                                                                          performance period ending on 31 December 2026 (vesting in March 2027 with an
                                                                          additional post vest 2 year holding period).

 c)      Price(s) and volume(s)

                                                                                                              Price(s)          Volume(s)
                                                                                            (i)               Nil               355,191
                                                                                            (ii)              Nil               334,272
                                                                                            (iii)             Nil               190,369
                                                                                            (iv)              Nil               158,653
                                                                                            (v)               Nil               41,484
                                                                                            (vi)              Nil               170,334

 d)      Aggregated information

         - Aggregated volume                                              1,250,303

         - Price                                                          Nil

 e)      Date of the transaction                                          31 October 2024

 f)      Place of the transaction                                         Outside a trading venue

 

 

Amanda Mellor

Company Secretary

 

About Haleon

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose
to deliver better everyday health with humanity. Haleon's product portfolio
spans five major categories - Oral Health, Pain Relief, Respiratory Health,
Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its
long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu,
Otrivin, Polident, parodontax and Centrum - are built on trusted science,
innovation and deep human understanding.

 

For more information, please visit www.haleon.com (http://www.haleon.com/)
.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHGCBDBBSGDGSB